NCT01590238 is a Phase 3 clinical trial of PRFM treatment in Alopecia, sponsored by The New York Eye & Ear Infirmary.

Who is sponsoring NCT01590238?

NCT01590238 is sponsored by The New York Eye & Ear Infirmary.

What drugs are being tested in NCT01590238?

Interventions in NCT01590238: PRFM treatment.

Is NCT01590238 still recruiting?

NCT01590238 is currently completed. Last updated 29 December 2016.

Are results published for NCT01590238?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-12-29 · How we verify

NCT01590238

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)

Completed Phase 3 Results posted Last updated 29 December 2016

What this trial tests

Phase 3 trial testing PRFM treatment in Alopecia in 15 participants. Completed in 1 November 2013.

Timeline

1 May 2012

Primary endpoint
1 September 2013

1 November 2013

Quick facts

Lead sponsor	The New York Eye & Ear Infirmary
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 May 2012
Primary completion	1 September 2013
Estimated completion	1 November 2013
Sites	1 location across United States

Drugs / interventions tested

PRFM treatment — full drug profile →

Conditions studied

Alopecia — all drugs for Alopecia →

Sponsor

The New York Eye & Ear Infirmary — full company profile →

Who can join

Adults 18 to 75, any sex, with Alopecia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hair Density Change After Three Treatments
Time frame: 6 months after initial visit
Hair density index at calibrated distance from glabella in a 2 cm x 2 cm midline square at 6 month follow up visit as a percentage of initial (pre-treatment) hair density index, measured using a proprietary hair densitometer.

Sponsor's own description

Clinical alopecia occurs due to miniaturization of the hair shafts as well as loss of active production of hair shafts. PRFM has been shown to induce dermal angiogenesis, and anecdotal findings of improvement of hair appearance after PRFM injection in the scalp suggest that PRFM may play a role in the treatment of thinning hair. Patients will be treated on a monthly basis with intradermal injections of autologous PRFM for 3 months. Changes in hair density will be assessed by comparing pre- and post-treatment photographs and non-invasive measurements of hair density at 1, 2, 3, 4 and 6 months after initial treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alopecia

Currently open trials in the same condition.

NCT07422376 — Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variation · NA · recruiting
NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
NCT06998680 — 6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair · NA · recruiting
NCT05484973 — Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss · NA · recruiting
NCT06215469 — Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) · NA · recruiting

Other The New York Eye & Ear Infirmary trials

Trials by the same sponsor.

NCT05324189 — Automated AI-based System for Early Diagnosis of Diabetic Retinopathy · unknown
NCT04863391 — Telemedicine in Age-Related Macular Degeneration · unknown
NCT04087356 — Age-related Macular Degeneration (AMD) and Cardiovascular Disease · unknown
NCT03918590 — Post Intravitreal Injection Topical NSAID vs. Patching · Phase 4 · unknown
NCT02984813 — Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01590238 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The New York Eye & Ear Infirmary
Last refreshed: 29 December 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01590238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing